|
CN112279834A
|
|
FGFR4 inhibitor, preparation method, pharmaceutical composition and application thereof
|
|
CN112279836A
|
|
N- (5-methyl-1H-pyrazol-3-yl) pyridine-2-amine compound and preparation method thereof
|
|
CN112250658A
|
|
Formylated bicyclol and preparation method thereof
|
|
CN112225738A
|
|
Compounds as TLR8 agonists, methods of preparation, compositions, and uses thereof
|
|
CN112250657A
|
|
Bicyclol dimer, preparation method and application thereof
|
|
CN112225737A
|
|
Compound with HDAC (Histone deacetylase) inhibitory activity, preparation method, composition and application
|
|
CN112094177A
|
|
Preparation method and application of eugenol dimer B
|
|
CN112028880A
|
|
Oxitinib dimer, preparation method and application thereof
|
|
CN112245386A
|
|
Dexamethasone sodium phosphate injection and preparation method thereof
|
|
CN112263553A
|
|
Bismuth potassium citrate tablet, preparation method and application thereof
|
|
CN111961081A
|
|
Preparation method of (R) -2- (2-methoxypropyl phosphate) -adenine
|
|
CN111892580A
|
|
2-amino-4- (isoindoline-2-yl) pyrimidine-5-formamide derivative, preparation method and application
|
|
CN112107580A
|
|
Spleen tyrosine kinase inhibitor preparation composition and preparation method thereof
|
|
CN112067506A
|
|
Method for measuring viscosity of bismuth potassium citrate-containing preparation
|
|
CN111925313A
|
|
Compound with PDE4 inhibitory activity, preparation method, composition and application
|
|
CN112220785A
|
|
PDE4 inhibitor pharmaceutical composition, preparation method and application thereof
|
|
CN112285040A
|
|
Method for determining free bismuth in bismuth-containing preparation
|
|
CN111675705A
|
|
Preparation method of 4- (4-aminophenyl) morpholine-3-one derivative
|
|
CN111732575A
|
|
N- (3- (pyrimidine-2-yl) phenyl) benzene sulfonamide derivative, pharmaceutical composition, preparation method and application
|
|
CN111732547A
|
|
Refining method and application of olapari
|
